Janus Henderson Group plc Acquires 9.9% Stake in Minerva Neurosciences, Inc.

Janus Henderson Group plc (JHG) filed a Schedule 13G on May 15, 2026, reporting a significant new ownership stake in Minerva Neurosciences, Inc. (NERV). As of the event date on March 31, 2026, the filer beneficially owns 4,307,759 shares of common stock, representing 9.9% of the company. This holding includes 9,000 pre-funded series A Warrants and 4,500 series A Warrants. Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over managed portfolios. Notably, the Janus Henderson Biotech Innovation Master Fund Ltd. is identified as having the right to receive dividends or sale proceeds from more than 5% of the issuer's common stock. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This position marks a substantial increase from a previously reported 0% ownership.